CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH The draft guidance outlines considerations for study design, trial conduct, data collection, subject safety, and new drug application requirements.
The US FDA has recently released its first draft guidance directed towards researchers studying the therapeutic potential of psychedelic drugs, marking a significant step towards their possible future medical application.
Key Points:
- The FDA has released its first draft guidance for researchers studying psychedelic drugs for potential medical treatments.
- The guidance specifically addresses “classic psychedelics,” such as psilocybin and LSD, and entactogens or empathogens like MDMA.
- Tiffany Farchione, MD, FAPA, director of the Division of Psychiatry in the FDA’s Center for Drug Evaluation and Research, highlights the potential of psychedelic drugs for treating mood, anxiety, and substance use disorders.
Additional Points:
- Due to the psychoactive effects of psychedelic drugs, the FDA emphasizes the need for stringent safety measures during clinical development.
- Investigators need to consider unique factors when designing their clinical trials, given the characteristics of psychedelic drugs.
- The document also discusses the role of psychotherapy in psychedelic drug development, safety monitoring, and characterizing dose-response and treatment durability.
- The public is encouraged to provide feedback on the draft guidance within 60 days.
Conclusion:
- The FDA’s first draft guidance on the research and potential therapeutic use of psychedelic drugs is a milestone step that paves the way for future medical treatments using such substances, given the consideration of outlined safety and study design measures.
Psychiatry Latest Posts
- Burnout, Depression, and Diminished Well-Being among Physicians
- Recommendations to Distinguish Behavioural Variant Frontotemporal Dementia from Psychiatric Disorders
- Why Antidepressant Duloxetine Was Recalled
- A List of Drugs Linked to Dementia
“By publishing this draft guidance, the FDA hopes to outline the challenges inherent in designing psychedelic drug development programs and provide information on how to address these challenges. The goal is to help researchers design studies that will yield interpretable results that will be capable of supporting future drug applications.”
Tiffany Farchione, MD, FAPA
